Centrum is bullish on Abbott India has recommended buy rating on the stock with a target price of Rs 7530 in its research report dated May 15, 2018.
Broker Research
Centrum's research report on Abbott India
AIL’s EBIDTA for Q4FY18 was lower than our expectations whereas net profit was higher than our expectations. The pharma major’s revenue grew 10% YoY, margin improved 470bps to 13.5% and net profit grew 138% YoY. That said, the company’s eleven leading brands grew faster than the market and are likely to drive future growth.
Outlook
We maintain our Buy rating on AIL with a TP of Rs7,530 based on 24x March’20E EPS of Rs313.6. we have revised FY19E and FY20E EPS by 6% and 7% respectively. We expect AIL to perform well due to its strong brands, new product launches and presence in the high-margin vaccine segment.For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.